All In Biotech

Drug Trial Radar · NCT03379727

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for "7+3" or "5+2" Chemotherapy

Last checked: Nov 19, 2026Latest source record: Feb 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

301

Actual

Start

Feb 13, 2018

Primary completion

Jul 9, 2021

Study completion Jul 9, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to gather and evaluate additional safety and efficacy data on the combination of midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who were eligible for standard induction and consolidation

Conditions

  • Acute Myeloid Leukemia

Interventions

  • MidostaurinDrug

    Induction Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for 1 - 2 cycles; a cycle = 28 days; Consolidation Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for up to 4 cycles; Maintenance Phase: Continuous dosing (days 1 - 28) for up yo 12 cycles or until relapse, unacceptable toxicity, death, physician's decision, subject/guardian decision, protocol deviation, study termination by Sponsor, lost to follow-up, technical problems, pregnancy, subject withdrew consent, or until the end of study, whichever event occurred first.

  • CytarabineDrug

    Induction Phase (standard dose) (7 + 3 arm): 100-200 mg/m2/day by Continuous intravenous infusion (CIVI) days 1-7 (168 hours infusion); Induction Phase (5 + 2 arm): 100 mg/m2/day by CIVI days 1-5; Consolidation Phase: 1-3 g/m2 infusion over 3 hours every 12 h on days 1, 3 and 5, up to 4 cycles based on age and per investigator discretion

  • anthracycline ((daunorubicin or idarubicin): Induction Phase onlyDrug

    daunorubicin (7 + 3 arm): 60-90 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); daunorubicin (5 + 2 arm): 60 mg/m2/day by IV push on days 1-2; idarubicin (7 + 3 arm): 12 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); idarubicin (5 + 2 arm): 12 mg/m2/day by IV push on days 1-2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Adverse Events (AEs), Grade 3 & 4 AEs, Serious Adverse Events (SAEs), AEs Leading to Discontinuation, and Deaths up to 24 Months (M24).Time frame: Baseline up to approximatly 24 months

Locations

86 sites in 15 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Varna, Bulgaria

  • Novartis Investigative Site

    Zagreb, Croatia

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Tallinn, Estonia

  • Novartis Investigative Site

    Helsinki, Finland

  • Novartis Investigative Site

    Oulu, Finland

  • Novartis Investigative Site

    Tampere, Finland

  • Novartis Investigative Site

    Besançon, France

  • Novartis Investigative Site

    Clamart, France

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Dijon, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Limoges, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Metz, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pierre-Bénite, France

  • Novartis Investigative Site

    Poitiers, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Bayonne, Bayonne Cedex, France

  • Novartis Investigative Site

    Saint Priest En Jarez, Pays de la Loire Region, France

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Szeged, Hungary

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Ancona, AN, Italy

  • Novartis Investigative Site

    Avellino, AV, Italy

  • Novartis Investigative Site

    Bergamo, BG, Italy

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Brescia, BS, Italy

  • Novartis Investigative Site

    Cuneo, CN, Italy

  • Novartis Investigative Site

    Cosenza, CS, Italy

  • Novartis Investigative Site

    San Giovanni Rotondo, FG, Italy

  • Novartis Investigative Site

    Florence, FI, Italy

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.